Research Progress on Neuroprotection of Insulin-like Growth Factor-1 towards Glutamate-Induced Neurotoxicity.

Abstract

Insulin-like growth factor-1 (IGF-1) and its binding proteins and receptors are widely expressed in the central nervous system (CNS), proposing IGF-1-induced neurotrophic actions in normal growth, development, and maintenance. However, while there is convincing evidence that the IGF-1 system has specific endocrine roles in the CNS, the concept is emerging that IGF-I might be also important in disorders such as ischemic stroke, brain trauma, Alzheimer's disease, epilepsy, etc., by inducing neuroprotective effects towards glutamate-mediated excitotoxic signaling pathways. Research in rodent models has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 was administered by different routes, and several clinical studies have shown safety and promise of efficacy in neurological disorders of the CNS. Focusing on the relationship between IGF-1-induced neuroprotection and glutamate-induced excitatory neurotoxicity, this review addresses the research progress in the field, intending to provide a rationale for using IGF-I clinically to confer neuroprotective therapy towards neurological diseases with glutamate excitotoxicity as a common pathological pathway.

• Authors: Lijun Ge, Shuyuan Liu, Limor Rubin, Philip Lazarovici, Wenhua Zheng
• Journal: Cells (Cells) Vol. 11 Issue 4 (02 14 2022) ISSN: 2073-4409 [Electronic] Switzerland
• PMID: 35203315 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Neuroprotective Agents
• Glutamic Acid
• Insulin-Like Growth Factor I

Topics

• Glutamic Acid (toxicity)
• Humans
• Insulin-Like Growth Factor I (metabolism)
• Nervous System Diseases
• Neuroprotection
• Neuroprotective Agents (pharmacology)
• Neurotoxicity Syndromes (drug therapy)